1. 3016Long-term survival and safety with selexipag in patients with pulmonary arterial hypertension: results from the GRIPHON study and its open-label extension. (28th August 2018) Authors: Galie, N; Gaine, S; Channick, R; Ghofrani, H A; Hoeper, M; Lang, I; McLaughlin, V; Preiss, R; Rubin, L; Shiraga, Y; Simonneau, G; Sitbon, O; Tapson, V; Chin, K Journal: European heart journal Issue: Volume 39(2018)Supplement 1 Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. Body fluid status in patients with pulmonary arterial hypertension and chronic thromboembolic pulmonary hypertension. (3rd October 2022) Authors: Yogeswaran, A; Husain-Seyed, F; Tello, K; Sommer, N; Rako, Z A; Ghofrani, H A; Seeger, W; Richter, M J; Gall, H Journal: European heart journal Issue: Volume 43(2022)Supplement 2 Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
3. Changes in cMRI parameters following a switch to riociguat from phosphodiesterase type 5 inhibitors (PDE5i) in patients with pulmonary arterial hypertension: a REPLACE substudy. (14th October 2021) Authors: Rosenkranz, S; Benza, R L; Ghofrani, H A; Gruenig, E; Hoeper, M M; Peacock, A; Simonneau, G; Vizza, D; Meier, C; Vogtlaender, K; Vonk-Noordegraaf, A Journal: European heart journal Issue: Volume 42(2021)Supplement 1 Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗